340 related articles for article (PubMed ID: 16434583)
21. Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer.
Roato I; Gorassini E; Buffoni L; Lyberis P; Ruffini E; Bonello L; Baldi I; Ciuffreda L; Mussa A; Ferracini R
Lung Cancer; 2008 Jul; 61(1):109-16. PubMed ID: 18061306
[TBL] [Abstract][Full Text] [Related]
22. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
[TBL] [Abstract][Full Text] [Related]
23. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
24. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
25. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
26. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.
Ibrahim T; Sacanna E; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Ricci R; Serra L; Kang Y; Amadori D
Clin Breast Cancer; 2011 Dec; 11(6):369-75. PubMed ID: 21764390
[TBL] [Abstract][Full Text] [Related]
27. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
28. [Bone turnover markers in the detection of bone metastases in primary lung cancer].
Kong QQ; Tu CQ; Dou QY; Wang JP; Sun TW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May; 36(3):397-9. PubMed ID: 15931879
[TBL] [Abstract][Full Text] [Related]
29. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
30. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
31. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
[TBL] [Abstract][Full Text] [Related]
32. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of bone and tumour markers in patients with malignant diseases.
Oremek GM; Weis A; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):987-90. PubMed ID: 12820336
[TBL] [Abstract][Full Text] [Related]
34. Comparison of whole body MRI and radioisotope bone scintigram for skeletal metastases detection.
Chan Y; Chan K; Lam W; Metreweli C
Chin Med J (Engl); 1997 Jun; 110(6):485-9. PubMed ID: 9594253
[TBL] [Abstract][Full Text] [Related]
35. [Clinical features of pathologically confirmed metastatic bone tumors--a report of 390 cases].
Xu DL; Zhang XT; Wang GH; Li FB; Hu JY
Ai Zheng; 2005 Nov; 24(11):1404-7. PubMed ID: 16552972
[TBL] [Abstract][Full Text] [Related]
36. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
Mihai R; Stevens J; McKinney C; Ibrahim NB
Eur J Surg Oncol; 2006 Jun; 32(5):511-5. PubMed ID: 16564154
[TBL] [Abstract][Full Text] [Related]
37. Markers of bone turnover do not predict bone metastases in breast cancer.
Seibel MJ; Koeller M; Van der Velden B; Diel I
Clin Lab; 2002; 48(11-12):583-8. PubMed ID: 12465741
[TBL] [Abstract][Full Text] [Related]
38. [Diagnostic value of whole-body MRI and bone scintigraphy in the detection of osseous metastases in patients with breast cancer--A Prospective Double-Blinded Study at two Hospital Centers].
Ohlmann-Knafo S; Kirschbaum M; Fenzl G; Pickuth D
Rofo; 2009 Mar; 181(3):255-63. PubMed ID: 19229791
[TBL] [Abstract][Full Text] [Related]
39. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement.
Roato I; Grano M; Brunetti G; Colucci S; Mussa A; Bertetto O; Ferracini R
FASEB J; 2005 Feb; 19(2):228-30. PubMed ID: 15550550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
